ICER gets $5.2M to fund drug pricing analyses

The Institute for Clinical and Economic Review received a $5.2 million grant from the Laura and John Arnold Foundation and launched a new program to analyze cost effectiveness, comparative effectiveness, and budget impacts of newly approved drugs. ICER founder and President Steve Pearson told BioCentury the donation will support the program for two years.

Pearson said the non-profit expects to publish 15-20 reports a year, starting with its evaluation of high cholesterol treatment Repatha evolocumab from Amgen Inc. (NASDAQ:AMGN) on Sept. 8 and heart failure drug Entresto sacubitril/valsartan from Novartis AG (NYSE:NVS; SIX:NOVN) on Sept. 10. ...